Isis Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets | |||||
(In Thousands) | |||||
March 31, | December 31, | ||||
2011 | 2010 | ||||
(unaudited) | |||||
Assets: | |||||
Cash, cash equivalents and short-term investments | $426,822 | $472,353 | |||
Other current assets | 10,573 | 10,784 | |||
Property, plant and equipment, net | 37,680 | 35,703 | |||
Other assets | 30,867 | 31,637 | |||
Total assets | $505,942 | $550,477 | |||
Liabilities and stockholders' equity: | |||||
Other current liabilities | $21,007 | $31,388 | |||
Current portion of deferred contract revenue | 73,392 | 74,502 | |||
2 5/8% convertible subordinated notes | 134,964 | 132,895 | |||
Long-term obligations, less current portion | 15,085 | 15,867 | |||
Investment in Regulus Therapeutics Inc. | 1,726 | 870 | |||
Long-term deferred contract revenue | 32,065 | 50,413 | |||
Stockholders' equity | 227,703 | 244,542 | |||
Total liabilities and stockholders' equity | $505,942 | $550,477 | |||
